Hansa Medical's Annual Report for 2014 is now available on the company’s website, www.hansamedical.com. The Annual Report is posted to shareholders and other stakeholders who specifically request it. For further information please contact the company by telephone +46 46-16 56 70 or e-mail info@hansamedical.com. For further information, please contact: Hansa Medical AB Göran Arvidson, CFO and acting CEO Mobile: 46 706-33 30 42 E-mail: goran.arvidson@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.
Hansa Medical publishes the Annual Report for 2014
| Source: Hansa Medical AB
Attachments
